Current and historical daily PE Ratio for Sailong Pharmaceutical Group Co Ltd (
SZSE:002898
) from 2017 to Jun 05 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Sailong Pharmaceutical Group stock (SZSE:002898) PE ratio as of Jun 05 2024 is 194.35.
More Details
Sailong Pharmaceutical Group Co Ltd (SZSE:002898) PE Ratio (TTM) Chart
Sailong Pharmaceutical Group Co Ltd (SZSE:002898) PE Ratio (TTM) Historical Data
View and export this data going back to 2017. Start your Free Trial
Total 1198
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Sailong Pharmaceutical Group PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-05 | 194.3 | 2024-03-27 | 199.1 |
| 2024-06-04 | 199.6 | 2024-03-26 | 195.3 |
| 2024-06-03 | 204.1 | 2024-03-25 | 196.4 |
| 2024-05-31 | 210.4 | 2024-03-22 | 200.7 |
| 2024-05-30 | 209.1 | 2024-03-21 | 208.2 |
| 2024-05-29 | 213.5 | 2024-03-20 | 213.1 |
| 2024-05-28 | 210.2 | 2024-03-19 | 212.0 |
| 2024-05-27 | 217.4 | 2024-03-18 | 221.4 |
| 2024-05-24 | 216.3 | 2024-03-15 | 227.1 |
| 2024-05-23 | 216.3 | 2024-03-14 | 206.4 |
| 2024-05-22 | 219.8 | 2024-03-13 | 187.6 |
| 2024-05-21 | 220.9 | 2024-03-12 | 189.6 |
| 2024-05-20 | 224.1 | 2024-03-11 | 181.8 |
| 2024-05-17 | 225.2 | 2024-03-08 | 179.4 |
| 2024-05-16 | 223.7 | 2024-03-07 | 176.7 |
| 2024-05-15 | 221.5 | 2024-03-06 | 178.9 |
| 2024-05-14 | 226.1 | 2024-03-05 | 176.0 |
| 2024-05-13 | 233.5 | 2024-03-04 | 184.6 |
| 2024-05-10 | 227.0 | 2024-03-01 | 181.1 |
| 2024-05-09 | 237.2 | 2024-02-29 | 182.7 |
| 2024-05-08 | 231.1 | 2024-02-28 | 180.0 |
| 2024-05-07 | 230.7 | 2024-02-27 | 200.0 |
| 2024-05-06 | 228.0 | 2024-02-26 | 187.3 |
| 2024-04-30 | 220.0 | 2024-02-23 | 179.4 |
| 2024-04-29 | 219.1 | 2024-02-22 | 173.6 |
| 2024-04-26 | 210.7 | 2024-02-21 | 165.4 |
| 2024-04-25 | 210.4 | 2024-02-20 | 162.9 |
| 2024-04-24 | 206.5 | 2024-02-19 | 161.6 |
| 2024-04-23 | 205.7 | 2024-02-08 | 155.4 |
| 2024-04-22 | 194.8 | 2024-02-07 | 141.3 |
| 2024-04-19 | 200.7 | 2024-02-06 | 155.4 |
| 2024-04-18 | 205.2 | 2024-02-05 | 165.8 |
| 2024-04-17 | 207.6 | 2024-02-02 | 181.1 |
| 2024-04-16 | 192.8 | 2024-02-01 | 193.6 |
| 2024-04-15 | 214.3 | 2024-01-31 | 198.6 |
| 2024-04-12 | 238.3 | 2024-01-30 | 212.4 |
| 2024-04-11 | 233.0 | 2024-01-29 | 230.4 |
| 2024-04-10 | 242.4 | 2024-01-26 | 233.1 |
| 2024-04-09 | 246.7 | 2024-01-25 | 228.9 |
| 2024-04-08 | 249.1 | 2024-01-24 | 219.4 |
| 2024-04-03 | 240.7 | 2024-01-23 | 219.8 |
| 2024-04-02 | 240.2 | 2024-01-22 | 220.2 |
| 2024-04-01 | 245.0 | 2024-01-19 | 235.6 |
| 2024-03-29 | 243.3 | 2024-01-18 | 238.6 |
| 2024-03-28 | 242.8 | 2024-01-17 | 241.3 |
Sailong Pharmaceutical Group Co Ltd (SZSE:002898) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Sailong Pharmaceutical Group Co Ltd
ISIN : CNE1000032S5
Share Class Description:
SZSE:002898: Class ACompare
Compare
Traded in other countries / regions
002898.China IPO Date
2017-09-12Description
Zhuhai Sailong Pharmaceutical Co Ltd is the pharmaceutical company. It is mainly engaged in the development, production, marketing and technical services of pharmaceuticals. The company's products are mainly concentrated in the fields of the nervous system, cardiovascular and digestive system. The product range includes monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers